Angiogenesis inhibitors in the treatment of colorectal cancerIQBAL, Syma; LENZ, Heinz-Josef.Seminars in oncology. 2004, Vol 31, Num 6, pp 10-16, issn 0093-7754, 7 p., SUP17Article

Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment ApproachSTINTZING, Sebastian; LENZ, Heinz-Josef.Clinical cancer research (Print). 2014, Vol 20, Num 12, pp 3064-3070, issn 1078-0432, 7 p.Article

Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!STINTZING, Sebastian; LENZ, Heinz-Josef.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 16, pp 2203-2220, issn 1465-6566, 18 p.Article

Targeted therapy and pharmacogenomic programsIQBAL, Syma; LENZ, Heinz Josef.Cancer. 2003, Vol 97, Num 8, pp 2076-2082, issn 0008-543X, 7 p., SUPConference Paper

Cyclooxygenase-2 inhibitors in colorectal cancerSTOEHLMACHER, Jan; LENZ, Heinz-Josef.Seminars in oncology. 2003, Vol 30, Num 3, pp 10-16, issn 0093-7754, 7 p., SUP6Article

Future directions in the use of antiangiogenic agents in patients with colorectal cancerHOFF, Paulo M.Seminars in oncology. 2004, Vol 31, Num 6, pp 17-21, issn 0093-7754, 5 p., SUP17Article

EGFR, HER2 and VEGF pathways : Validated targets for cancer treatmentPRESS, Michael F; LENZ, Heinz-Josef.Drugs (Basel). 2007, Vol 67, Num 14, pp 2045-2075, issn 0012-6667, 31 p.Article

The role of proteasome inhibitors in solid tumors : Proteasome inhibitionPARK, David J; LENZ, Heinz-Josef.Annals of medicine (Helsinki). 2004, Vol 36, Num 4, pp 296-303, issn 0785-3890, 8 p.Article

Angiogenesis and its role in colorectal tumor and metastasis formationELLIS, Lee M.Seminars in oncology. 2004, Vol 31, Num 6, pp 3-9, issn 0093-7754, 7 p., SUP17Article

Pharmacogenomics in colorectal cancerLENZ, Heinz Josef.Seminars in oncology. 2003, Vol 30, Num 4, pp 47-53, issn 0093-7754, 7 p., SUP15Article

Panitumumab safety for treating colorectal cancerSTREMITZER, Stefan; SEBIO, Ana; STINTZING, Sebastian et al.Expert opinion on drug safety. 2014, Vol 13, Num 6, pp 843-851, issn 1474-0338, 9 p.Article

Predictive Molecular Classifiers in Colorectal Cancer : COLORECTAL CANCERBOHANES, Pierre; LABONTE, Melissa J; WINDER, Thomas et al.Seminars in oncology. 2011, Vol 38, Num 4, pp 576-587, issn 0093-7754, 12 p.Article

Assessing the in vivo efficacy of biologic antiangiogenic therapiesWILSON, Peter M; LABONTE, Melissa J; LENZ, Heinz-Josef et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 1, pp 1-12, issn 0344-5704, 12 p.Article

Markers of Response for the Antiangiogenic Agent BevacizumabLAMBRECHTS, Diether; LENZ, Heinz-Josef; DE HAAS, Sanne et al.Journal of clinical oncology. 2013, Vol 31, Num 9, pp 1219-1230, issn 0732-183X, 12 p.Article

Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, bay 43-9006, in patients with advanced, refractory solid tumorsCLARK, Jeffrey W; EDER, Joseph P; RYAN, David et al.Clinical cancer research. 2005, Vol 11, Num 15, pp 5472-5480, issn 1078-0432, 9 p.Article

Pancreatic Cancer: Medical Management (Novel Chemotherapeutics)PAEZ, David; LABONTE, Melissa J; LENZ, Heinz-Josef et al.Gastroenterology clinics of North America. 2012, Vol 41, Num 1, issn 0889-8553, x, 189-209 [22 p.]Article

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cellsFAZZONE, William; WILSON, Peter M; LABONTE, Melissa J et al.International journal of cancer (Print). 2009, Vol 125, Num 2, pp 463-473, issn 0020-7136, 11 p.Article

Colorectal cancerCUNNINGHAM, David; ATKIN, Wendy; LENZ, Heinz-Josef et al.Lancet (British edition). 2010, Vol 375, Num 9719, pp 1030-1047, issn 0140-6736, 18 p.Article

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly scheduleGARCIA, Agustin A; PUJARI, Mahesh; JEFFERS, Susan et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 1, pp 75-82, issn 0344-5704, 8 p.Article

Can we predict the response to epidermal growth factor receptor targeted therapy?MANEGOLD, Philipp C; LURJE, Georg; POHL, Alexandra et al.Targeted oncology. 2008, Vol 3, Num 2, pp 87-99, issn 1776-2596, 13 p.Article

Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancerGARCIA, Agustin A; LEICHMAN, Lawrence; BARANDA, Joaquina et al.International journal of gastrointestinal cancer. 2003, Vol 34, Num 2-3, pp 79-86, issn 1537-3649, 8 p.Article

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancerPARK, David J; STOEHLMACHER, Jan; WU ZHANG et al.International journal of colorectal disease (Print). 2002, Vol 17, Num 1, pp 46-49, issn 0179-1958Article

Cancer Dormancy: A Model of Early Dissemination and Late Cancer RecurrencePAEZ, David; LABONTE, Melissa J; BOHANES, Pierre et al.Clinical cancer research (Print). 2012, Vol 18, Num 3, pp 645-653, issn 1078-0432, 9 p.Article

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the Thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activityMANDOLA, Michael V; STOEHLMACHER, Jan; MULLER-WEEKS, Susan et al.Cancer research (Baltimore). 2003, Vol 63, Num 11, pp 2898-2904, issn 0008-5472, 7 p.Article

Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsiesANTON, Pete A; POLES, Michael A; ELLIOTT, Julie et al.Journal of virological methods. 2001, Vol 95, Num 1-2, pp 65-79, issn 0166-0934Article